Online inquiry

IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15983MR)

This product GTTS-WQ15983MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets Felcat IL31 gene. The antibody can be applied in Feline atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Felinized
RefSeq XM_011287838.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 105261056
UniProt ID A0A337S7E6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15983MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ458MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ643MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ15921MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ1689MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ7663MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ13507MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX002
GTTS-WQ8713MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ14825MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW